varenicline + placebo

Phase 2/3Terminated

0 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Friedreich's Ataxia

Conditions

Friedreich's Ataxia

Trial Timeline

May 1, 2009 → May 1, 2010

NCT ID

NCT00803868

About varenicline + placebo

varenicline + placebo is a phase 2/3 stage product being developed by Pfizer for Friedreich's Ataxia. The current trial status is terminated. This product is registered under clinical trial identifier NCT00803868. Target conditions include Friedreich's Ataxia.

What happened to similar drugs?

0 of 7 similar drugs in Friedreich's Ataxia were approved

Approved (0) Terminated (0) Active (7)

🔄Interferon γ-1bAmgenPhase 3

🔄interferon γ-1bAmgenPhase 3

🔄Interferon γ-1b + PlaceboAmgenPhase 3

🔄idebenone + PlaceboSanthera PharmaceuticalsPhase 3

🔄Idebenone + Idebenone + PlaceboSanthera PharmaceuticalsPhase 3

🔄IdebenoneSanthera PharmaceuticalsPhase 3

🔄Idebenone + PlaceboSanthera PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02856581	Phase 3	Terminated	Sep 29, 2017	Apr 15, 2022	Lung Carcinoma
NCT01934023	Phase 2	Completed	Sep 1, 2013	Aug 1, 2015	Schizophrenia
NCT01850953	Approved	Completed	Jun 1, 2013	May 1, 2015	Craving
NCT01639560	Approved	Completed	Jan 1, 2013	Jun 1, 2016	Smoking
NCT01244061	Approved	Completed	Dec 1, 2010	Nov 1, 2012	Smoking Cessation
NCT01078298	Approved	Completed	Mar 1, 2010	Jun 1, 2012	Smoking Cessation
NCT01071187	Phase 2	UNKNOWN	Mar 1, 2010	Sep 1, 2011	Alcohol Dependence
NCT01010204	Approved	Completed	Jan 1, 2010	Mar 1, 2013	Smoking Cessation
NCT00992771	Phase 2	Completed	Oct 1, 2009	Apr 1, 2011	Spinocerebellar Ataxia Type 3
NCT00918307	Phase 3	Completed	Oct 1, 2009	Jul 1, 2014	HIV Infections
NCT00977249	Phase 2/3	UNKNOWN	Sep 1, 2009	Dec 1, 2011	Tobacco Dependence
NCT00744978	Phase 2	Completed	Jul 1, 2009	Nov 1, 2010	Alzheimer's Disease
NCT00803868	Phase 2/3	Terminated	May 1, 2009	May 1, 2010	Friedreich's Ataxia
NCT00835900	Phase 2	Completed	Mar 1, 2009	Jul 1, 2015	Smoking Cessation
NCT00944554	Approved	Completed	Oct 1, 2008	May 1, 2011	Recurrence
NCT00749944	Approved	Completed	Sep 1, 2008	Aug 1, 2009	Smoking Cessation
NCT00747643	Pre-clinical	Completed	Sep 1, 2008	Aug 1, 2010	Tobacco Dependence
NCT00937508	Approved	UNKNOWN	Jun 1, 2008	Jun 1, 2011	Smoking
NCT00595868	Phase 2	Completed	Mar 1, 2008	Jan 1, 2010	Tobacco Use Disorder
NCT00602927	Pre-clinical	Completed	Nov 1, 2007	Aug 1, 2008	Nicotine Dependence

Competing Products

11 competing products in Friedreich's Ataxia

See all competitors

Product	Company	Stage	Hype Score
Interferon γ-1b	Amgen	Phase 3	40
interferon γ-1b	Amgen	Phase 3	40
Interferon γ-1b + Placebo	Amgen	Phase 3	40
Lu AA24493 + Placebo	Lundbeck	Phase 2	32
Omeveloxolone	Biogen	Pre-clinical	30
Placebo + EPI-743 400 mg + EPI-743 200 mg	PTC Therapeutics	Phase 2	32
SGT-212	Solid Biosciences	Phase 1	30
idebenone + Placebo	Santhera Pharmaceuticals	Phase 3	30
Idebenone + Idebenone + Placebo	Santhera Pharmaceuticals	Phase 3	30
Idebenone	Santhera Pharmaceuticals	Phase 3	30
Idebenone + Placebo	Santhera Pharmaceuticals	Phase 3	30